Top news of December: Intermittent fasting, MI awareness lacking, new generic apixaban and more
Click Here to Manage Email Alerts
Healio and Cardiology Today present a list of the most-viewed cardiology articles in December. This month, our readers were most interested in benefits of intermittent fasting, the effect of chili pepper consumption on the heart, oral hygiene and CV health, the FDA approval of apixaban generics and more.
Intermittent fasting may benefit in metabolic syndrome
Patients with metabolic syndrome who limited their eating to a 10-hour window in addition to statin and antihypertensive medications had reductions in weight, BP, HbA1c and atherogenic lipids, according to a study published in Cell Metabolism. Read more
Chili pepper consumption may reduce CVD, all-cause mortality
Regular dietary intake of chili peppers conferred lower risk for all-cause and CVD death in Italian adults, independent of CVD risk factors or adherence to a Mediterranean diet, according to research published in the Journal of the American College of Cardiology. Read more
Many Americans unaware of MI signs, symptoms
Nearly half of all U.S. citizens do not know the five signs and symptoms of MI and, depending on the sociodemographic subgroup, may not know any at all, according to research published in JAMA Network Open. Read more
Good oral hygiene may lower risk for HF, AF
Patients with improved oral hygiene had a lower risk for atrial fibrillation and HF compared with those with poor oral hygiene, according to a study published in the European Journal of Preventive Cardiology. Read more
EMPERIAL top-line results: Empagliflozin for HFpEF, HFrEF fails to improve exercise ability
Boehringer Ingelheim and Eli Lilly and Co. announced negative top-line results for its EMPERIAL-Reduced and EMPERIAL-Preserved trials, noting that the SGLT2 inhibitor empagliflozin did not meet the primary endpoint of improvements in exercise ability according to the 6-minute walk test from baseline to 12 weeks compared with placebo in patients with chronic HF with reduced and preserved ejection fraction. Read more
Icosapent ethyl may act on plaque
In a Commentary by Thomas Das, MD; Rachit M. Vakil, MD, MPH; Roger S. Blumenthal, MD; and Seth S. Martin, MD, MHS, the authors review results of the EVAPORATE trial and current evidence on how high-dose eicosapentaenoic acid may slow coronary plaque progression. Read more
FDA approves first generic versions of apixaban
The FDA announced it approved two applications for the first generic versions of apixaban tablets to reduce risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Read more